GlassScriptPhysician profile
Keely Dyan Schoonover
NPI 1083129167
$960.60
in general payments reported to CMS, 2019-2025
17 companies · $24.43 in 2025
The $24.43 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.39 · 2022: $428 · 2023: $295 · 2024: $116 · 2025: $24.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $216.48 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $177.48 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $116.03 | 2021-2023 | |
| Lilly USA, LLC | $74.45 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $67.98 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $38.01 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $37.84 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $36.30 | 2022 | |
| Amgen INC. | $35.71 | 2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $29.71 | 2024 | Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $29.18 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.96 | 2021 | |
| Merck Sharp & Dohme LLC | $18.93 | 2023 | Verquvo, Belsomra |
| Corium, LLC | $18.63 | 2023 | Azstarys |
| Nevro Corp. | $16.57 | 2023 | Senza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $13.85 | 2024 | |
| Sunovion Pharmaceuticals INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Schoonover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.